Sander Kersten, Wageningen University, The Netherlands, discusses the physiology of ANGPTL4 and how this compares with ANGPTL3 and ANGPTL8, and the potential of ANGPTL4 inhibition for reduction of TG levels and cardiovascular risk.
Please login or create a FREE account to view this content
Educational Supporters of the 10th Closed Scientific Expert Meeting of the Editorial Board
Principal supporters:

Guest supporters:
